ArticleFrontiers in molecular biosciences2026
Radiomics machine learning model based on multi-sequence MRI for predicting Ki-67 expression level in glioblastoma.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glioblastoma (GBM) is the most aggressive primary malignant brain tumor in adults, with median overall survival around 15 months. The Ki- 67 proliferation index is an important marker of proliferative activity and has prognostic relevance in GBM; however, its assessment requires surgical tissue and may be affected by sampling bias. Developing a non-invasive preoperative method to estimate Ki-67 expression may provide adjunctive information for risk assessment, while it should not be regarded as a stand-alone determinant of treatment decisions. Methods: This retrospective study included 269 histologically confirmed GBM patients from The Fourth Affiliated Hospital of Xinjiang Medical University. Patients were classified into low (n = 61) and high (n = 208) Ki-67 expression groups using a 20% threshold, selected according to published GBM Ki-67 stratification literature and local pathology reporting practice. Multi-sequence MRI scans were acquired at 3.0T, including T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR), and contrast-enhanced T1WI (CET1WI). A total of 8,612 radiomic features were extracted from three-dimensional tumor volumes across all sequences. After reducing dimensionality via Pearson correlation coefficient filtering and LASSO regression, machine learning models were built using BernoulliNB, GaussianNB, SVM, and AdaBoost classifiers for each sequence independently and a Combined model integrating all four sequences. Model performance metrics included AUC, accuracy, sensitivity, specificity, F1 score, calibration curves, and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) were used to interpret model predictions. Results: Baseline demographics (gender, BMI, age) did not differ significantly between groups. The Combined model integrating all sequences achieved the highest predictive accuracy, with AUCs of 0.915 (95% CI: 0.874-0.956) in the training set and 0.746 (95% CI: 0.614-0.879) in the test set, outperforming single-sequence models. Notably, the Combined model attained sensitivity of 0.930 and negative predictive value of 0.972 in training, indicating strong identification of high Ki-67 expression. Calibration curves and DCA demonstrated good model calibration and clinical utility. Discussion: A radiomics-based multi-sequence MRI machine learning model may serve as a non-invasive adjunct for preoperative Ki-67 estimation in GBM. The combined sequence approach outperformed single modalities, and SHAP analysis enhanced interpretability; however, clinical application requires external validation and outcome-based evidence before use in treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.